| Nucara Pharmacy #31 | |
| 234 Central Ave N, Valley City, North Dakota 58072 | |
| (701) 845-2652 |
| Name | Nucara Pharmacy #31 |
|---|---|
| Organization Name | Nudak Ventures North Dakota, Llc |
| Location | 234 Central Ave N, Valley City, North Dakota 58072 |
| Type | Pharmacy |
| Phone | (701) 845-2652 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Haemacure Corporation (TSX : HAE) reported today on current activities and released the financial results of its third quarter ended July 31.
A*STAR scientists have identified a biomarker of the most lethal form of brain tumours in adults- glioblastoma multiforme. The scientists found that by targeting this biomarker and depleting it with a potential drug, they were able to prevent the progression and relapse of the brain tumour.
Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for Atorvastatin Calcium Tablets, 10 mg, 20 mg, 40 mg and 80 mg.
Pfizer Inc. announced today that it has initiated the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for crizotinib (PF-02341066), an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors are ALK-positive. Pfizer expects to complete the submission in the first half of 2011.
In an editorial opening the 2006 Jan issue of Psychotherapy and Psychosomatics Giovanni A. fava (University of Bologna) criticizes the current subdivision of clinical medicine in subspecialties.
› Verified 4 days ago
| NPI Number | 1548282403 |
| Organization Name | NUDAK VENTURES NORTH DAKOTA, LLC |
| Doing Business As | NUCARA PHARMACY #31 |
| Type | Pharmacy |
| Address | 234 Central Ave N, Valley City, ND 58072 |
| Phone Number | 701-845-2652 |
News Archive
Haemacure Corporation (TSX : HAE) reported today on current activities and released the financial results of its third quarter ended July 31.
A*STAR scientists have identified a biomarker of the most lethal form of brain tumours in adults- glioblastoma multiforme. The scientists found that by targeting this biomarker and depleting it with a potential drug, they were able to prevent the progression and relapse of the brain tumour.
Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for Atorvastatin Calcium Tablets, 10 mg, 20 mg, 40 mg and 80 mg.
Pfizer Inc. announced today that it has initiated the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for crizotinib (PF-02341066), an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors are ALK-positive. Pfizer expects to complete the submission in the first half of 2011.
In an editorial opening the 2006 Jan issue of Psychotherapy and Psychosomatics Giovanni A. fava (University of Bologna) criticizes the current subdivision of clinical medicine in subspecialties.
› Verified 4 days ago
News Archive
Haemacure Corporation (TSX : HAE) reported today on current activities and released the financial results of its third quarter ended July 31.
A*STAR scientists have identified a biomarker of the most lethal form of brain tumours in adults- glioblastoma multiforme. The scientists found that by targeting this biomarker and depleting it with a potential drug, they were able to prevent the progression and relapse of the brain tumour.
Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for Atorvastatin Calcium Tablets, 10 mg, 20 mg, 40 mg and 80 mg.
Pfizer Inc. announced today that it has initiated the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for crizotinib (PF-02341066), an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors are ALK-positive. Pfizer expects to complete the submission in the first half of 2011.
In an editorial opening the 2006 Jan issue of Psychotherapy and Psychosomatics Giovanni A. fava (University of Bologna) criticizes the current subdivision of clinical medicine in subspecialties.
› Verified 4 days ago
Nucara Pharmacy #31 Type: Pharmacy Location: 234 Central Ave N, Valley City, North Dakota 58072 Phone: (701) 845-2652 | |
Thrifty White Pharmacy #059 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 120 W Main St, Valley City, North Dakota 58072 Phone: (701) 845-1763 |